264 related articles for article (PubMed ID: 23931953)
1. The development of the rotigotine transdermal patch: a historical perspective.
Waters C
Neurol Clin; 2013 Aug; 31(3 Suppl):S37-50. PubMed ID: 23931953
[TBL] [Abstract][Full Text] [Related]
2. Rotigotine transdermal system: developing continuous dopaminergic delivery to treat Parkinson's disease and restless legs syndrome.
Benitez A; Edens H; Fishman J; Moran K; Asgharnejad M
Ann N Y Acad Sci; 2014 Nov; 1329():45-66. PubMed ID: 25145951
[TBL] [Abstract][Full Text] [Related]
3. An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome.
Elshoff JP; Cawello W; Andreas JO; Mathy FX; Braun M
Drugs; 2015 Apr; 75(5):487-501. PubMed ID: 25795100
[TBL] [Abstract][Full Text] [Related]
4. Rotigotine transdermal patch for the treatment of Parkinson's Disease.
Perez-Lloret S; Rey MV; Ratti PL; Rascol O
Fundam Clin Pharmacol; 2013 Feb; 27(1):81-95. PubMed ID: 22320451
[TBL] [Abstract][Full Text] [Related]
5. Rotigotine transdermal patch for the treatment of Parkinson's disease and restless legs syndrome.
Boroojerdi B; Wolff HM; Braun M; Scheller DK
Drugs Today (Barc); 2010 Jul; 46(7):483-505. PubMed ID: 20683503
[TBL] [Abstract][Full Text] [Related]
6. Rotigotine transdermal patch in the management of Parkinson's disease (PD) and its night-time use for PD-related sleep disorders.
Antonini A; Bernardi L; Calandrella D; Mancini F; Plebani M
Funct Neurol; 2010; 25(1):21-5. PubMed ID: 20626993
[TBL] [Abstract][Full Text] [Related]
7. Rotigotine: a novel dopamine agonist for the transdermal treatment of Parkinson's disease.
Zareba G
Drugs Today (Barc); 2006 Jan; 42(1):21-8. PubMed ID: 16511608
[TBL] [Abstract][Full Text] [Related]
8. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study.
Sieb JP; Themann P; Warnecke T; Lauterbach T; Berkels R; Grieger F; Lorenzl S
Curr Med Res Opin; 2015 May; 31(5):967-74. PubMed ID: 25772231
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of rotigotine clinical trials: effects on motor and nonmotor symptoms of Parkinson's disease.
Lyons KE; Pahwa R
Neurol Clin; 2013 Aug; 31(3 Suppl):S51-9. PubMed ID: 23931954
[TBL] [Abstract][Full Text] [Related]
10. Rotigotine: the first new chemical entity for transdermal drug delivery.
McAfee DA; Hadgraft J; Lane ME
Eur J Pharm Biopharm; 2014 Nov; 88(3):586-93. PubMed ID: 25173087
[TBL] [Abstract][Full Text] [Related]
11. Rotigotine Transdermal Patch: A Review in Parkinson's Disease.
Frampton JE
CNS Drugs; 2019 Jul; 33(7):707-718. PubMed ID: 31243728
[TBL] [Abstract][Full Text] [Related]
12. Switching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective.
Chung SJ; Asgharnejad M; Bauer L; Benitez A; Boroojerdi B; Heidbrede T; Little A; Kim HJ
Expert Rev Neurother; 2017 Jul; 17(7):737-749. PubMed ID: 28548894
[TBL] [Abstract][Full Text] [Related]
13. Rotigotine transdermal patch: a review of its use in the management of Parkinson's disease.
Baldwin CM; Keating GM
CNS Drugs; 2007; 21(12):1039-55. PubMed ID: 18020483
[TBL] [Abstract][Full Text] [Related]
14. Treatment of motor and NMS of Parkinson's disease with the rotigotine transdermal system.
Lyons KE
Neurol Clin; 2013 Aug; 31(3 Suppl):vii-ix. PubMed ID: 23931955
[No Abstract] [Full Text] [Related]
15. Rotigotine: transdermal dopamine agonist treatment of Parkinson's disease and restless legs syndrome.
Splinter MY
Ann Pharmacother; 2007 Feb; 41(2):285-95. PubMed ID: 17213296
[TBL] [Abstract][Full Text] [Related]
16. Transdermal Patch of Rotigotine Attenuates Freezing of Gait in Patients with Parkinson's Disease: An Open-Label Comparative Study of Three Non-Ergot Dopamine Receptor Agonists.
Ikeda K; Hirayama T; Takazawa T; Kawabe K; Iwasaki Y
Intern Med; 2016; 55(19):2765-2769. PubMed ID: 27725534
[TBL] [Abstract][Full Text] [Related]
17. Rotigotine transdermal patch in combination therapy for Parkinson's disease--observations in routine clinical practice.
Ceballos-Baumann A; Häck HJ
Curr Med Res Opin; 2011 Oct; 27(10):1899-905. PubMed ID: 21867400
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain.
Rascol O; Zesiewicz T; Chaudhuri KR; Asgharnejad M; Surmann E; Dohin E; Nilius S; Bauer L
J Clin Pharmacol; 2016 Jul; 56(7):852-61. PubMed ID: 26626320
[TBL] [Abstract][Full Text] [Related]
19. Rotigotine transdermal system for the treatment of Parkinson's disease.
Pham DQ; Nogid A
Clin Ther; 2008 May; 30(5):813-24. PubMed ID: 18555929
[TBL] [Abstract][Full Text] [Related]
20. Transdermal rotigotine: a new non-ergot dopamine agonist for the treatment of Parkinson's disease.
Naidu Y; Chaudhuri KR
Expert Opin Drug Deliv; 2007 Mar; 4(2):111-8. PubMed ID: 17335409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
